Previous 10 |
home / stock / iugnf / iugnf news
(NewsDirect) Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive the company’s Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXINIA) has seen the first patients dosed in the intravenous and intratumoral (I...
(NewsDirect) Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive it has been a busy and productive start to the new year with a number of presentations including at the JP Morgan Healthcare Conference. The company also presented an oral abstract and several poster sessions on it...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Product Development Platforms Reach Clinical Trial Milestones. A Phase 1 dose escalation trial has begun treating patients with CF-hNIS Vaccinia, a product from Imugene's oncolytic virus platform. The trial will enroll patients with metastatic or advanced solid tumors. The company has also pub...
Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates. The stock price is up 38%+ since our last coverage in September 2021, however, the company is in need of...
Stimulating the body’s immune system to attack tumors is a promising way to treat cancer. Scientists are working on two complementary strategies to achieve that: taking off the brakes that tumors put on the immune system; and “stepping on the gas,” or delivering molecules ...
Three Technology Platforms With Innovative Products Imugene is developing novel immunotherapies that fight cancer by using oncoviruses, gene transfer, and antigen delivery. Its three technology platforms are in development to kill cancer cells directly, replace the use of monoclonal antibodies...
Imugene (OTCPK:IUGNF) and Celularity (NASDAQ:CELU) have entered into a research collaboration to develop the combination of Imugene’s CD19 oncolytic virus technology and Celularity’s CD19 targeting allogeneic chimeric antigen receptor (CAR) T cellular therapy, CyCART-19, for the...
News, Short Squeeze, Breakout and More Instantly...
Imugene Ltd Company Name:
IUGNF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Imugene Ltd (ASX:IMU) managing director and CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss the strategic partnership the company has formed with Kincell Bio, LLC that involves the sale of Imugene's Current Good Manufacturing Practice (CGMP) complia...
The expansion trial is expected to enrol 10 patients with bile tract cancers (cholangiocarcinoma) Interim results from the MAST trial have demonstrated positive responses in gastrointestinal cancers, particularly in cholangiocarcinoma where one patient treated with CF33-hNIS (VAXINIA) achieve...
(NewsDirect) Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Proactive’s Jonathan Jackson to discuss enrolment for a pivotal expansion study targeting bile tract cancer (cholangiocarcinoma) patients. This follows the successful completion of the fifth high-dose cohort in the intr...